Nevro (NVRO) Shares are Up 21.56%

Nevro (NVRO) : Traders are bullish on Nevro (NVRO) as it has outperformed the S&P 500 by a wide margin of 20.42% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 21.49%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 21.56% in the last 1 week, and is up 21.66% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 17.59% and the 50-Day Moving Average is 25.88%. Nevro (NYSE:NVRO): stock turned positive on Friday. Though the stock opened at $97.67, the bulls momentum made the stock top out at $98.2 level for the day. The stock recorded a low of $96.16 and closed the trading day at $97.89, in the green by 0.71%. The total traded volume for the day was 520,617. The stock had closed at $97.2 in the previous days trading.


The company Insiders own 12.1% of Nevro shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.77% . Institutional Investors own 98.5% of Nevro shares. During last six month period, the net percent change held by insiders has seen a change of -15.19%. Also, Equity analysts at the Brokerage firm JMP Securities maintains its rating on Nevro (NYSE:NVRO). The rating major has initiated the coverage with market outperform rating on the shares. The Analysts at JMP Securities raises the price target from $90 per share to $110 per share. The rating by the firm was issued on August 9, 2016.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Companys Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Companys Senza system creates electrical impulses from two hertz to 10 kilohertz, including its HF10 therapy, which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.